ERK inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9879029
SERIAL NO

15529641

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ELI LILLY AND COMPANYLILLY CORPORATE CENTER INDIANAPOLIS INDIANA 46285 UNITED STATES OF AMERICA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cortez, Guillermo S Indianapolis, US 11 8
Joseph, Sajan Carmel, US 31 244
McLean, Johnathan Alexander Indianapolis, US 13 18
McMillen, William Thomas Indianapolis, US 17 116
Rodriguez, Michael John Indianapolis, US 11 50
Zhao, Gaiying Carmel, US 12 39

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 30, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 30, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00